Targets › PTK2B
1 program from 1 company in 20 trials: 12 Phase 2, 7 Phase 1, 1 Phase 3; Oncology; next expected readout Dec 2026.
Non-receptor protein-tyrosine kinase that regulates reorganization of the actin cytoskeleton, cell polarization, cell migration, adhesion, spreading and bone remodeling. Plays a role in the regulation of the humoral immune response, and is required for normal levels of marginal B-cells in the spleen and normal migration of splenic B-cells. (UniProt, Q14289)
Open in Phaseline: the race on PTK2B, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Verastem | defactinib Focal adhesion kinase 1 inhibitor; Protein tyrosine kinase 2 beta inhibitor | PTK2, PTK2B | Phase 3 | Low Grade Serous Ovarian Cancer; Low Grade Ovarian Serous Adenocarcinoma; Non Small Cell Lung Cancer; KRAS Activating Mutation … | Dec 2026 |
Low Grade Serous Ovarian Cancer (2) Low Grade Ovarian Serous Adenocarcinoma (1) Non Small Cell Lung Cancer (1) KRAS Activating Mutation (1) Advanced Lymphoma (1) Mesonephric Gynecologic Cancer (1) Low-Grade Serous Ovarian Cancer (1) Pancreas Cancer (1) Thyroid Cancer (1) Endometrioid Cancer (1) Gastric Cancer (1) Advanced Colorectal Cancer (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.